NEJM· @NEJM · X·· 8 天前精选AI 评分88
AI 导读
NEJM 报道,3期 TRIUMPH-1 试验中,三重激素受体激动剂 retatrutide 使肥胖受试者体重显著下降,同时减少膝骨关节炎疼痛和阻塞性睡眠呼吸暂停事件。完整试验结果与研究摘要见 https://nej.md/4ycgSHz。
推荐理由
3期TRIUMPH-1结果显示retatrutide在减重之外还改善膝骨关节炎疼痛与睡眠呼吸暂停事件,可供评估三重激动剂的综合获益。
正文
In the phase 3 TRIUMPH-1 trial involving participants with obesity, retatrutide, a triple hormone receptor agonist, resulted in substantial weight reduction and a decrease in knee osteoarthritis pain and obstructive sleep apnea events. Full trial results and Research Summary: https://nej.md/4ycgSHz
来源:NEJM · x.com